Javed Khan
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Year:
2026
B7-H3 is a cell surface protein overexpressed in many solid tumors and an attractive target for chimeric antigen receptor (CAR) T cell therapy. The most clinically advanced B7-H3 CARs are derived from murine monoclonal antibodies (mAbs) 376.96 and MGA271, which are now in phase 1/11 trials. However, non-human mAb sequences can provoke immune responses, leading to CAR T-cell rejection and therapeutic failure. Although scFv humanization reduces this risk, residual foreign residues within the variable domains remain. To overcome this limitation, we used in vitro phage display to generate fully human B7-H3-specific scFvs for CAR design. In pancreatic cancer, neuroblastoma, and glioblastoma xenograft models, CAR T cells incorporating the lead human binder Y111 were well tolerated and demonstrated superior antitumor activity compared with 376.96- and MGA271-based CARs. Y111 CAR treatment induced complete responses, tumor rejection, and significant survival benefits, identifying Y111 as a promising fully human B7-H3 CAR for solid tumors.
Year:
2026
PURPOSE Molecular markers increasingly influence risk-stratified treatment selection for pediatric rhabdomyosarcoma (RMS). This study aims to integrate molecular and clinical data to produce individualized prognosis predictions that can further improve treatment selection. METHODS Clinical variables and somatic mutation data for 20 genes from 641 patients with RMS in the United Kingdom and the United States were used to develop three Cox proportional hazard models for predicting event-free survival (EFS). The Baseline Clinical (BC) model included treatment location, age, fusion status, and risk group. The Gene Enhanced 2 (GE2) model added TP53 and MYOD1 mutations to the BC predictors. The Gene Enhanced 6 (GE6) model further included NF1 , MET , CDKN2A , and MYCN mutations, selected through least absolute shrinkage and selection operator regression. Model performance was assessed using likelihood ratio tests and optimism-adjusted, bootstrapped validation and calibration metrics. RESULTS The GE6 model demonstrated superior predictive performance compared with the BC model ( P < .001) and GE2 model ( P < .001). The GE6 model achieved the highest discrimination with a time-dependent area under the receiver operating characteristic curve of 0.766. Mutations in TP53 , MYOD1 , CDKN2A , MET , and MYCN were associated with higher hazards, while NF1 mutation correlated with lower hazard. Individual prognosis predictions varied between models in ways that may suggest different treatments for the same patient. For example, the 5-year EFS for a 10-year-old patient with high-risk, fusion-negative, NF1 -positive disease was 50.0% (95% CI, 39 to 64) from BC but 76% (64 to 90) from GE6. CONCLUSION Incorporating molecular markers into RMS prognosis models improves prognosis predictions. Individualized prognosis predictions may suggest alternative treatment regimens compared with traditional risk-classification schemas. Improved clinical variables and external validation are required before implementing these models into clinical practice.
Year:
2025
Background: Ewing sarcoma (EWS) is a rare cancer of the bone and soft tissue, most prevalent in children and young adults. The treatment of EWS has progressed relatively little in over 30 years. Survival rates for patients, particularly those with metastatic and/or relapsed disease remain poor, highlighting the urgent need for innovative treatment options. Methods: Here, we have explored the therapeutic potential of the oncolytic Maraba virus strain MG1 using various in vitro models of EWS, including established cell lines, doxorubicin-resistant derivatives, spheroid cultures and primary patient-derived Ewing sarcoma cell cultures. We examined the direct oncolytic activity of MG1 and its ability to stimulate the immune-mediated killing of EWS by human healthy donor peripheral blood mononuclear cells. Results: We show that MG1 undergoes productive replication and exerts direct oncolysis of established EWS cell lines, doxorubicin-resistant EWS cell lines and patient-derived Ewing sarcoma cell cultures more recently established from tumours. In contrast, primary mesenchymal stem cells (the likely cell of origin of EWS) were resistant to MG1, with IFN-I being a major determinant of tumour cell selectivity. MG1-treated PBMC produced IFN-I and killed EWS cells in vitro, in a natural killer (NK) cell-dependent manner. Conclusions: The ability of MG1 to kill EWS cells directly and stimulate NK cell cytotoxicity against this tumour suggests that MG1 may provide therapeutic benefit for EWS patients where the efficacy of conventional treatments is currently limited.
Year:
2025
10025 Background: The Molecular Characterization Initiative (MCI), a partnership between the Children’s Oncology Group (COG) and the NCI’s Childhood Cancer Data Initiative (CCDI), provides standardized genomic profiling of tumors and germline for subjects with newly diagnosed pediatric soft tissue sarcomas (STS). Here, we report on STS patients 20 histologies were enrolled, most common being synovial sarcoma (n = 16, 8%). Of 49 patients with an initial diagnosis of undifferentiated sarcoma, round cell sarcoma, spindle cell sarcoma and sarcoma NOS, 32 underwent fusion testing, and 28 had WES: in 13 (40%) sequencing resulted in specific diagnosis [CIC::DUX4 in 5, BCOR::CCNB3 in 4, NTRK rearrangement in 2, SS18::SSX2 in 1 and EWSR1::ETV1 in 1], and 5 (15%) had rare fusions involving NUTM1 , NSD3 , EGFR and COL1A1 genes;16 exhibited somatic CNVs; 5(18%) had somatic mutations; and 2 (7%) carried germline variants in TP53 and RET genes. Overall, MCI results, as reported by institutions, facilitated clinical trial enrollment in 15%, receipt of targeted therapy outside trials in 17%, and diagnostic refinement in 25% of tested patients, respectively. Conclusions: CCDI’s MCI program provides comprehensive genomic profiling of pediatric and adolescent STS, uncovering distinct somatic genetic alterations, rare fusions, actionable genomic targets and germline variants.
Year:
2025
Prediction of RAS pathway mutations using a trained CNN. A, Workflow for deep learning of RAS pathway mutations from FN-RMS WSIs. B and C, Representative ( B ) H&E images and ( C ) class activation maps of a RAS pathway wild-type tumor and a tumor with a KRAS p.G12C mutation (VAF = 0.659). D, Confusion matrix for predictions on a test dataset. Micro F1, Macro F1, and Matthew's correlation coefficient shown below. E, Statistics for confusion matrix. F, Average ROC curve from holdout test data.
Year:
2025
Supplemental Figure S3. Sample partitioning for training and testing a RAS pathway mutation predictive model using K-fold cross-validation. Three independent experiments were trained on a random selection of samples for training, validation and testing.
Year:
2025
Deep learning of histologic features from RMS tumor tissue. A, (i) Samples are randomly selected for training, validation, or holdout test groups with k-fold cross validation. Networks were trained to recognize (ii) basic histological characteristics and (iii) features associated with FOXO1 fusion status, or (iv) other relevant RMS mutations. (v) A predictive model was also developed to predict disease risk using only an H&E image. B, Representative H&E images (left), expert pathologist manual annotation (middle), and pixel-level segmentation results of the A.I. algorithm (right). C, Histogram of the weighted IoU scores from holdout test data ( n = 29). Samples corresponding to B are indicated. D, Average and weighted intersection over union (IoU) scores of A.I. performance across a 3-fold cross-validation set compared with a pathologist manual annotation.
Year:
2025
Supplemental Table S1. Whole slide image tissue segmentation statistics by an expert pathologist and probability prediction using a trained convolutional neural network. Supplemental Table S2. Clinical and molecular characteristics of FN-RMS samples used for training models for mutation prediction. Yellow boxes indicate genes included in defining the RAS pathway. Supplemental Table S3. Clinical information with COG risk stratification of FN-RMS samples used for training a prognostication predictive CNN.
Year:
2025
TP53 gene mutation prediction from H&E images. A, Workflow for deep learning of TP53 mutations from FN-RMS WSIs. B and C, Representative ( B ) H&E images and ( C ) class activation maps of a TP53 wild-type tumor and a tumor with a TP53 p.P278T mutation (VAF = 0.474). D, Confusion matrix for predictions on a test dataset. Micro F1, Macro F1, and Matthew's correlation coefficient shown below. E, Performance statistics for TP53 mutation prediction. F, Average ROC curve for TP53 mutation prediction using holdout test data. G, Dot plot of TP53 mutant samples ( n = 15) showing relationship between TP53 mutation VAF and A.I. positive prediction probability. Statistical analysis was performed using the Mann–Whitney U test.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (39)
Jun Wei
National Cancer Institute
Angelina Vaseva
Assistant Professor/Research
University of Texas Health Science Center at San Antonio
Corinne M. Linardic
Duke University
Berkley E. Gryder
Case Western Reserve University
Graham Cook
Professor of Molecular and Cellular Immunology
University of Leeds
Sharon Diskin
Associate Professor
University of Pennsylvania
Douglas Hawkins
Professor
University of Washington
Benjamin Stanton
Associate Professor with Tenure
Nationwide Children’s Hospital and The Ohio State University College of Medicine
Anand Patel
Assistant Member
St. Jude Children's Research Hospital
Peter K. Bode
-
Natasha Caplen
Principal Investigator
National Cancer Institute
Adam Durbin
Assistant Member
St. Jude Children's Research Hospital
Susanne Andrea Gatz
University of Birmingham
Peter Giannoudis
Professor
University of Leeds
Damianos Skopelitis
Lead Scientist
St. Jude Children's Research Hospital
Mark Hatley
Associate Member
St. Jude Children's Research Hospital
Philip Lupo
Professor
Emory University
Mark Zobeck
Baylor College of Medicine
Kristopher Bosse
Assistant Professor
Children's Hospital of Philadelphia
Yun Wei
Assistant Professor
University of Texas Southwestern Medical Center
Sapna Oberoi
Associate Professor
University of Manitoba
Liping Yang
Assistant Professor
The Ohio State University Wexner Medical Center
Fiona Errington-Mais
Associate Professor of Cancer Immunology
University of Leeds
GuoJun Yu
Staff Scientist
National Institutes of Health
Raditya Utama
Director of Bioinformatics Core
Cold Spring Harbor Laboratory
Silvia Pomella
RTT
University of Rome Tor Vergata
Christopher Vakoc
Assistant Professor
St. Jude Children's Research Hospital
Stephen X. Skapek
University of Texas Southwestern Medical Center
Rossella Rota
Group Leader
Ospedale Pediatrico Bambino Gesù
Jack Shern
Head, Tumor Evolution and Genomics Section
National Institutes of Health
JAMES CRONK
Assistant Professor
Cincinnati Children's Hospital Medical Center
Eleanor Chen
Assistant Professor
University of Washington
Michael Scheurer
Professor
Baylor College of Medicine
Yong Yean Kim
Assistant Professor
Stanford University
Dennis McGonagle
University of Leeds
Carol J Thiele
Deputy Chief
Institute of Cancer Research
Katie Hebron
Assistant Professor
Purdue University
Simone Hettmer
University Medical Center Freiburg
Rosandra Kaplan
Principal Investigator
National Cancer Institute
Make your next move.
Prepare your application
Review drafts before you send them.